[New advances in targeted therapy for breast cancer].

Objective: Breast cancer is a kind of malignant tumor which seriously endangers women's health. With the development of molecular biology technology and the further understanding of pathogenesis, the treatment of breast cancer has entered a new era of molecular targeted therapy, and has been making new progress. At present, molecular targeted drugs for the treatment of breast cancer keep emerging, mainly including endocrine therapy targeting estrogen and progesterone receptor (ER/PR), targeted drugs treatment for epidermal growth factor receptor-2 (HER-2); phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway inhibitors, anti-angiogenic drugs, poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA1/2 mutations, cyclin-dependent kinases (CDK) 4/6 inhibitors, etc. Because some signal pathway abnormalities may occur in different molecular types of breast cancer, the same targeted drugs are cross-used in different types.乳腺癌是一种严重危害女性健康的恶性肿瘤。随着对乳腺癌发病机制认识的不断深入和分子生物学技术的发展，乳腺癌的治疗进入了分子靶向治疗的新时代，并不断取得新进展。目前，针对乳腺癌的分子靶向药物不断出现，主要包括针对雌、孕激素受体的内分泌治疗药物，针对表皮生长因子受体2的药物，磷脂酰肌醇3激酶(PI3K)/Akt/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路抑制剂、抗血管生成药物，针对BRCA1/2突变的多聚二磷酸腺苷核糖聚合酶抑制剂，细胞周期蛋白依赖性激酶4/6抑制剂等。由于某些信号通路异常可发生于不同分子分型乳腺癌中，因此同一类分子靶向药物在不同分子分型乳腺癌中存在交叉使用。.